What is MIDI?
MIDI, Inc. is a veteran-owned biotechnology company recognized for its advanced capabilities in chromatographic data analysis and pattern recognition. The company's core offering, the Sherlock software, is a globally adopted platform for identifying bacteria, microbial communities, and diverse complex matrices such as edible oils and fire debris. MIDI provides comprehensive solutions, including dedicated microbial identification systems and specialized contract laboratory services for bacterial and fungal identification, primarily catering to research institutions and public health laboratories with its rapid and cost-effective analytical tools.
How much funding has MIDI raised?
MIDI has raised a total of $297K across 2 funding rounds:
Debt
$150K
Debt
$147K
Debt (2020): $150K with participation from PPP
Debt (2021): $147K led by PPP
Key Investors in MIDI
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for MIDI?
With a substantial large-scale late-stage funding context, MIDI is strategically positioned for accelerated growth and market expansion. The recent strategic investment signals confidence from backers in the company's technology and its potential to further penetrate markets requiring precise microbial identification and data analysis. Future developments are likely to focus on enhancing the Sherlock software's capabilities, expanding its application across new matrices, and potentially broadening its reach into adjacent sectors that rely on sophisticated biological data interpretation. This capital will likely fuel further research and development, bolster sales and marketing efforts, and solidify MIDI's leadership in the biotechnology analytics space.
See full MIDI company page
